SCHEMBL1877855

SCHEMBL1877855

CC(C)C(=O)NC1CCc2c(c3cc(Br)ccc3n2Cc2cccc(F)c2)C1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 10/20 0.48
HDAC1 Q13547 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
KRAS P01116 1/20 0.41
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
TBXA2R P21731 2/20 0.39
PTGDR Q13258 2/20 0.39
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12637031 1.00 PTGDR2 (0.48) PTGDR2HDAC1HDAC6KRASMTNR1A
SCHEMBL1871468 0.91 PTGDR2 (0.49) PTGDR2HDAC1HDAC6MTNR1AMTNR1B
SCHEMBL1877903 0.90 PTGDR2 (0.47) PTGDR2HDAC1HDAC6KRASMTNR1A
SCHEMBL1888567 0.90 PTGDR2 (0.47) PTGDR2HDAC1HDAC6KRASMTNR1A
SCHEMBL1877905 0.90 PTGDR2 (0.47) PTGDR2HDAC1HDAC6KRASMTNR1A
SCHEMBL1877449 0.90 PTGDR2 (0.50) PTGDR2HDAC1HDAC6MTNR1AMTNR1B
SCHEMBL12637171 0.89 PTGDR2 (0.49) PTGDR2HDAC1HDAC6MTNR1AMTNR1B
SCHEMBL1874282 0.89 PTGDR2 (0.44) PTGDR2HDAC1HDAC6MTNR1AMTNR1B
SCHEMBL1888136 0.89 PTGDR2 (0.47) PTGDR2HDAC1HDAC6MTNR1AMTNR1B
SCHEMBL1888137 0.89 PTGDR2 (0.47) PTGDR2HDAC1HDAC6MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
EP-1902026-B1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) LILLY CO ELI (US) 2010-02-17 EP disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
EP-1902026-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2008-03-26 EP disclosed
WO-2007002181-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2007-01-04 WO disclosed
WO-2007002181-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS AR, SHBG, CYP17A1 PTGDR2 437/4885HDAC1 634/4885HDAC6 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.